Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

MLA

Cascone, Tina, et al. “Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.” Cancer Discovery, vol. 13, no. 11, Nov. 2023, pp. 2394–411. EBSCOhost, https://doi.org/10.1158/2159-8290.CD-23-0436.

APA

Cascone, T., Kar, G., Spicer, J. D., García-Campelo, R., Weder, W., Daniel, D. B., Spigel, D. R., Hussein, M., Mazieres, J., Oliveira, J., Yau, E. H., Spira, A. I., Anagnostou, V., Mager, R., Hamid, O., Cheng, L.-Y., Zheng, Y., Blando, J., Tan, T. H., … Forde, P. M. (2023). Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discovery, 13(11), 2394–2411. https://doi.org/10.1158/2159-8290.CD-23-0436

Chicago

Cascone, Tina, Gozde Kar, Jonathan D Spicer, Rosario García-Campelo, Walter Weder, Davey B Daniel, David R Spigel, et al. 2023. “Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.” Cancer Discovery 13 (11): 2394–2411. doi:10.1158/2159-8290.CD-23-0436.